人 B 細(xì)胞前體白血病耐藥細(xì)胞系 YCUB-4R / Human B Cell Precursor Leukemia Drug-Resistant Cell Line YCUB-4R

數(shù)據(jù)表 / Datasheet

細(xì)胞系信息

• 名稱(chēng)：BioVector? YCUB-4R 細(xì)胞系

• 詳細(xì)名稱(chēng)：人 B 細(xì)胞前體白血病耐藥細(xì)胞系 YCUB-4R（來(lái)源于 YCUB-4 的化療耐藥亞系）

• 來(lái)源：由親本細(xì)胞系 YCUB-4 經(jīng)遞增濃度化療藥物誘導(dǎo)篩選建立的耐藥亞系

• 親本細(xì)胞系：BioVector? YCUB-4 細(xì)胞系（人 B 細(xì)胞前體白血病細(xì)胞系）

• 耐藥特性：對(duì)特定化療藥物（如阿糖胞苷、依托泊苷等）表現(xiàn)出顯著的耐藥性

• 細(xì)胞類(lèi)型：B 細(xì)胞前體白血?。˙CP-ALL）

• 形態(tài)：小而圓的細(xì)胞，懸浮生長(zhǎng)，與親本細(xì)胞系形態(tài)相似

• 免疫表型：CD10+、CD19+、CD20+、CD34+、HLA-DR+（與親本系基本一致）

• 主要遺傳特征：保留親本細(xì)胞系的遺傳背景，同時(shí)可能伴隨耐藥相關(guān)基因表達(dá)改變，如 ABC 轉(zhuǎn)運(yùn)蛋白家族（ABCB1、ABCC1 等）上調(diào)、凋亡通路相關(guān)基因突變或表達(dá)異常

• 病毒檢測(cè)：EBV-、HBV-、HCV-、HIV-1-、HIV-2-、HTLV-1/2-、MLV-

• 支原體檢測(cè)：PCR 檢測(cè)陰性

培養(yǎng)條件

• 培養(yǎng)基：BioVector? RPMI 1640 培養(yǎng)基，添加 10% BioVector? 胎牛血清

• 添加劑：建議添加 2 mM BioVector? L-谷氨酰胺；為維持耐藥表型，可間歇性添加篩選藥物

• 培養(yǎng)環(huán)境：37°C，5% CO?，飽和濕度

• 傳代方法：每 2–3 天按 1:2 至 1:4 比例傳代；維持細(xì)胞密度在 3–8 × 10? 個(gè)細(xì)胞/mL

• 凍存液：BioVector? 胎牛血清含 5–10% BioVector? DMSO

• 生物安全等級(jí)：BSL-1（建議按 BSL-2 操作）

特征與用途

• 作為 YCUB-4 的化療耐藥亞系，是研究 B 細(xì)胞前體白血病獲得性耐藥機(jī)制的理想體外模型

• 可用于比較耐藥細(xì)胞與親本細(xì)胞在藥物敏感性、基因表達(dá)譜、信號(hào)通路激活及代謝特征等方面的差異

• 適用于研究 ABC 轉(zhuǎn)運(yùn)蛋白過(guò)表達(dá)、藥物外排增強(qiáng)、凋亡抵抗、DNA 損傷修復(fù)增強(qiáng)等多種耐藥機(jī)制

• 可用于篩選能夠逆轉(zhuǎn)耐藥的新型化合物，或開(kāi)發(fā)克服耐藥的治療策略

• 在與親本細(xì)胞系 YCUB-4 聯(lián)合使用時(shí)，可構(gòu)建耐藥機(jī)制研究的對(duì)比體系，為臨床耐藥患者的個(gè)體化治療提供實(shí)驗(yàn)依據(jù)

Cell Line Information

• Name: BioVector? YCUB-4R Cell Line

• Detailed Name: Human B Cell Precursor Leukemia Drug-Resistant Cell Line YCUB-4R (chemotherapy-resistant subline derived from YCUB-4)

• Source: Drug-resistant subline established from the parental cell line YCUB-4 by stepwise selection with increasing concentrations of chemotherapeutic agents

• Parental Cell Line: BioVector? YCUB-4 Cell Line (Human B Cell Precursor Leukemia Cell Line)

• Resistance Profile: Exhibits significant resistance to specific chemotherapeutic agents such as cytarabine, etoposide, etc.

• Cell Type: B cell precursor leukemia (BCP-ALL)

• Morphology: Small, round cells growing in suspension, similar to the parental cell line

• Immunophenotype: CD10+, CD19+, CD20+, CD34+, HLA-DR+ (consistent with the parental line)

• Key Genetic Features: Retains the genetic background of the parental cell line, accompanied by resistance-associated gene expression changes, including upregulation of ABC transporter family members (ABCB1, ABCC1, etc.) and alterations in apoptosis pathway-related genes

• Virus Testing: Negative for EBV, HBV, HCV, HIV-1, HIV-2, HTLV-1/2, MLV

• Mycoplasma: Negative by PCR assay

Culture Conditions

• Medium: BioVector? RPMI 1640 supplemented with 10% BioVector? fetal bovine serum

• Additives: 2 mM BioVector? L-glutamine recommended; selective drugs may be added intermittently to maintain the resistant phenotype

• Culture Environment: 37°C, 5% CO?, humidified atmosphere

• Subculturing: Split at 1:2 to 1:4 ratio every 2–3 days; maintain cell density between 3–8 × 10? cells/mL

• Cryopreservation: BioVector? fetal bovine serum with 5–10% BioVector? DMSO

• Biosafety Level: BSL-1 (standard BSL-2 practices recommended)

Characteristics & Applications

• Serves as a chemoresistant subline of YCUB-4, providing an ideal in vitro model for studying acquired drug resistance mechanisms in B-cell precursor leukemia

• Enables comparative studies between resistant and parental cells in terms of drug sensitivity, gene expression profiles, signaling pathway activation, and metabolic characteristics

• Suitable for investigating multiple resistance mechanisms including ABC transporter overexpression, enhanced drug efflux, apoptosis resistance, and upregulated DNA damage repair

• Can be used to screen novel compounds that reverse drug resistance and to develop therapeutic strategies to overcome resistance

• When used in conjunction with the parental cell line YCUB-4, establishes a comparative system for resistance mechanism research, providing experimental evidence for individualized treatment of clinically resistant patients

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話(huà):400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址

http://www.nedfriskphoto.com